NCT03518814
Quality of Life in Patients With Multimetastatic Melanoma Currently in Remission (QUALM) No drug interventions Not Available Not Available completed NCT00866177
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma treatment 2 completed NCT02320305
MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery treatment 0 completed NCT02812693
Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification treatment 1 / 2 withdrawn NCT02318771
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer treatment 1 completed NCT01961115
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma treatment 2 completed NCT01307618
Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma treatment 2 terminated NCT01960634
Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma No drug interventions Not Available Not Available completed NCT01131234
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors treatment 1 completed NCT01196416
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma treatment 1 / 2 completed NCT02650635
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors treatment 1 terminated NCT02716948
SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine treatment 1 completed NCT01522820
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors treatment 1 completed NCT00019682
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma treatment 3 completed NCT01789827
Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy diagnostic 0 completed NCT01970527
Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma treatment 2 terminated NCT03154190
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer No drug interventions health_services_research Not Available unknown_status NCT02748564
Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma treatment 2 terminated NCT00026221
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma treatment 2 completed NCT02654821
Study With T-cel Receptor Gene Therapy in Metastatic Melanoma No drug interventions treatment 1 / 2 unknown_status NCT00387751
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma treatment 2 completed NCT01744171
Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma No drug interventions treatment 1 terminated NCT03229278
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma treatment 1 completed NCT01989559
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery prevention 1 completed NCT01460875
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma treatment Not Available completed NCT00110019
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery treatment 3 completed NCT01886235
Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery diagnostic Not Available completed NCT00397982
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma treatment 2 completed NCT03719131
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy treatment 2 active_not_recruiting NCT02941744
A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases prevention 1 / 2 completed NCT03112668
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners No drug interventions supportive_care Not Available completed NCT02858869
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases treatment 1 completed NCT05655312
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma treatment 1 / 2 recruiting NCT05970497
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors No drug interventions treatment 1 recruiting NCT06444815
A Study of VET3-TGI in Patients With Solid Tumors treatment 1 recruiting NCT00006003
SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated treatment 2 terminated NCT06284590
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients treatment 2 active_not_recruiting NCT01037790
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer treatment 2 completed NCT00036764
BMS-247550 in Treating Patients With Stage IV Melanoma treatment 2 completed NCT03353402
Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy No drug interventions treatment 1 unknown_status NCT01835184
Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery treatment 1 terminated NCT00438984
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma treatment 1 completed NCT01010984
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma No drug interventions treatment Not Available completed NCT00498979
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers treatment 1 completed NCT04478279
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors treatment 1 / 2 active_not_recruiting NCT01216787
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery treatment 2 withdrawn NCT01127451
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma treatment 2 completed NCT03200847
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma treatment 1 / 2 active_not_recruiting NCT01748747
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery treatment 0 completed NCT00003647
Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma treatment 3 completed NCT04305145
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis treatment 2 recruiting NCT04670445
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer No drug interventions health_services_research Not Available active_not_recruiting NCT03235245
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib treatment 2 active_not_recruiting NCT02263898
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations treatment 2 withdrawn NCT05732805
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma treatment 3 recruiting NCT05940311
Versatile Ampification Single-Molecule Detection in Liquid Biopsy No drug interventions Not Available Not Available recruiting NCT05303493
Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma No drug interventions treatment 1 recruiting NCT04007588
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma treatment 2 withdrawn NCT05370807
A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma treatment 2 recruiting NCT01703507
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma treatment 1 completed NCT04598009
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma treatment 2 recruiting NCT03161756
Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma treatment 1 / 2 unknown_status NCT06416085
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer supportive_care 2 recruiting NCT00030615
Decitabine in Treating Patients With Advanced Solid Tumors treatment 1 completed NCT06295159
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma treatment 0 recruiting NCT05402059
Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice No drug interventions Not Available Not Available recruiting NCT01120275
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma treatment 2 terminated NCT05176470
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients treatment 1 active_not_recruiting NCT00217542
Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery treatment 1 completed NCT00199342
A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma No drug interventions treatment 1 / 2 terminated NCT04526899
Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma treatment 2 active_not_recruiting NCT00085306
Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma treatment 2 completed NCT00553306
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma treatment 1 / 2 completed NCT06199713
Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients No drug interventions Not Available Not Available recruiting NCT00669019
Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery treatment 2 completed NCT01026324
Dinaciclib in Treating Patients With Stage III-IV Melanoma treatment 1 / 2 terminated NCT03190824
Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma treatment 2 unknown_status NCT02990416
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma treatment 1 / 2 unknown_status NCT06319196
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma treatment 2 recruiting NCT00019396
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer treatment 2 completed NCT01106235
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma treatment 1 terminated NCT01328535
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery treatment 2 completed NCT04154163
Appropriate Dosing to Optimise Personalised Cancer Treatments No drug interventions Not Available Not Available completed NCT00072163
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma treatment 2 completed NCT03385486
Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors treatment 1 recruiting NCT00121225
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma treatment 2 completed NCT00060125
Tipifarnib in Treating Patients With Metastatic Malignant Melanoma treatment 2 completed NCT00019448
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00281957
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery treatment 2 completed NCT00651157
Viral Therapy in Treating Patients With Metastatic Melanoma treatment 2 completed NCT04079166
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) treatment 2 recruiting NCT05171374
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE Not Available Not Available recruiting NCT00937482
Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer treatment 1 terminated NCT03161431
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab treatment 1 recruiting NCT00087373
Vaccine Therapy in Treating Patients With Metastatic Melanoma No drug interventions treatment 2 terminated NCT01519427
Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib treatment 2 terminated NCT00255762
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery treatment 2 completed NCT00089362
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors treatment 1 completed NCT04242329
Surgery of Melanoma Metastases After Systemic Therapy No drug interventions treatment 2 withdrawn NCT03340129
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) treatment 2 recruiting NCT02013492
Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery treatment 0 completed NCT01136967
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma treatment 2 completed NCT02203604
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery treatment 2 terminated NCT02094872
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic treatment 2 completed NCT02676869
Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma treatment 1 completed NCT00003646
Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma treatment 2 completed NCT00369395
A Study of Volociximab in Metastatic Melanoma treatment 2 terminated NCT02107755
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma treatment 2 completed NCT02166255
APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery No drug interventions treatment 1 completed NCT00655655
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors treatment 1 completed NCT02073123
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma treatment 1 / 2 completed NCT00006243
Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma treatment Not Available completed NCT00026143
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma treatment 2 completed NCT04455503
Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 treatment 1 / 2 terminated NCT02327390
Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma No drug interventions treatment 1 terminated NCT00019890
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma treatment 2 completed NCT05296564
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers treatment 1 / 2 recruiting NCT05070221
Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis treatment 1 unknown_status NCT05309421
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma treatment 2 recruiting NCT04139902
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma treatment 2 recruiting NCT01026051
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma No drug interventions treatment 2 terminated NCT05068453
Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis treatment 1 unknown_status NCT05598853
Intrathecal Double Checkpoint Inhibition treatment 1 recruiting NCT01875653
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma treatment 3 terminated NCT01133977
E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma treatment 1 / 2 completed NCT04410445
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence treatment 3 terminated NCT00436605
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma treatment 2 completed NCT04741997
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma treatment 0 recruiting NCT00243061
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma treatment 2 completed NCT04513028
Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma No drug interventions treatment Not Available recruiting NCT00024011
PS-341 in Treating Patients With Metastatic Malignant Melanoma treatment 2 completed NCT01217411
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer treatment 1 terminated NCT00979693
Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma treatment 2 withdrawn NCT03605771
Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain No drug interventions Not Available Not Available recruiting NCT00003509
Antineoplaston Therapy in Treating Patients With Stage IV Melanoma treatment 2 terminated NCT00438009
A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03) treatment 1 completed NCT02744209
Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients No drug interventions Not Available Not Available terminated NCT03153085
A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma treatment 2 completed NCT00003552
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma treatment 1 / 2 terminated NCT00082875
Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma treatment 2 terminated NCT04521075
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC treatment 1 / 2 unknown_status NCT06508775
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies other Not Available recruiting NCT00470470
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery treatment 2 completed NCT00349206
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma treatment 1 completed NCT04628806
Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells No drug interventions Not Available Not Available unknown_status NCT00005949
Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma treatment 2 completed NCT00119249
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery treatment 2 completed NCT00303836
Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma treatment 2 terminated NCT01376713
Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma treatment 2 completed NCT03620019
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma treatment 2 completed NCT00288041
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma treatment 2 completed NCT04059224
TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma treatment 2 completed NCT01103635
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma treatment 1 completed NCT00089063
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma treatment 2 completed NCT01339663
Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma treatment 1 completed NCT00087386
Tanespimycin in Treating Patients With Stage III-IV Melanoma treatment 2 terminated NCT00726739
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma treatment 2 completed NCT03991130
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma treatment 2 recruiting NCT04330430
Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease treatment 2 active_not_recruiting NCT00256230
Disulfiram in Patients With Metastatic Melanoma treatment 1 / 2 completed NCT01533948
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery treatment 2 terminated NCT04703426
Sargramostim (GM-CSF) + PD-1 treatment 2 withdrawn NCT04990726
Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors No drug interventions Not Available Not Available recruiting NCT06425926
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT01166126
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV treatment 2 terminated NCT01107665
Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma treatment 2 completed NCT04904120
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy No drug interventions diagnostic 1 completed NCT02054520
Immunotherapy Study for Patients With Stage IV Melanoma treatment 2 terminated NCT04142931
Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors treatment 1 unknown_status NCT05652673
Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial treatment Not Available recruiting NCT00112476
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors treatment 1 completed NCT02507076
Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma treatment Not Available withdrawn NCT06236360
Metastatic Melanoma Patients on Immunotherapy With Nutritive Intervention Based on Mediterranean Diet No drug interventions supportive_care Not Available recruiting NCT05286294
Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders treatment 2 recruiting NCT06093594
Investigating Participation Patterns Among Stage IV Melanoma Patients No drug interventions Not Available Not Available not_yet_recruiting NCT04045691
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment Not Available Not Available recruiting NCT00039091
Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer treatment 1 terminated NCT06204991
To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma treatment 1 not_yet_recruiting NCT04562129
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients treatment 2 recruiting NCT04356729
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma treatment 2 recruiting NCT00072189
A Phase II Study of UCN-01 in Metastatic Melanoma treatment 2 terminated NCT00085189
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma treatment 2 completed NCT05251389
FMT to Convert Response to Immunotherapy No drug interventions treatment 1 / 2 recruiting NCT01316692
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma No drug interventions treatment 2 terminated NCT06556004
Phase 1 Study Using TRIMELVax for Stage IIIC / IV Melanoma Patients No drug interventions treatment 1 active_not_recruiting NCT00945269
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma treatment 1 / 2 terminated NCT02236546
FDG-PET in Advanced Melanoma No drug interventions diagnostic Not Available terminated NCT02296112
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations treatment 2 completed NCT02145910
Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases treatment 1 withdrawn NCT00871481
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma treatment 1 / 2 completed NCT03879395
Surgery for Gastrointestinal Metastases of Malignant Melanoma - a Single Center Retrospective Cohort Study No drug interventions Not Available Not Available completed NCT00450255
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery treatment 2 completed NCT02306850
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma treatment 2 completed NCT01168050
Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. treatment 2 unknown_status NCT00074308
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers treatment 1 / 2 completed NCT01851408
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma treatment 2 withdrawn NCT01843738
Radiation Use During Vemurafenib Treatment treatment 1 withdrawn NCT01726738
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations treatment 2 completed